Senseonics Holdings has begun the first human clinical trial of Freedom, a next-generation continuous glucose monitoring (CGM) system designed without an external on-body transmitter. This implantable device communicates directly with mobile devices via Bluetooth and aims to provide a full year of accurate glucose monitoring with a single sensor. The trial marks a key step toward a potential commercial launch in 2028, following positive preclinical results. Freedom seeks to simplify diabetes management by making CGM less visible and burdensome for users.
Senseonics' new CGM system Freedom is the subject, with Pluang's health sector market data providing context. As of Oct 26, 2026 18:11 WIB, out of 150 health-sector US stocks priced on Pluang, 82 rose and 35 fell. Among notable movers, Inovio Pharmaceuticals Inc (INO) rose 4.55% to USD 0.94 with a typical hold time of 43 days, contrasting with Amylx Pharmaceuticals Inc (AMLX) at USD 28.35, up 4.23% but held for only 16 days, and Abeona Therapeutics Inc (ABEO) at USD 4.54, up 3.18% with a 27-day hold time.
Stryker Corporation has finalized its acquisition of ZuriMED, incorporating the FiberLocker System into its Sports Medicine offerings. This technology enhances rotator cuff repair by improving biomechanical strength, addressing a key clinical need. T...
Kratos Defense & Security Solutions announced it will release its third quarter 2026 financial results after market close on November 5, 2026. The company will hold a conference call at 2:00 p.m. Pacific Time to discuss its operations and financial p...
FOREWARN, a safety solutions provider for real estate professionals, introduced Community Alerts, a new feature that allows agents to flag phone numbers after concerning interactions. This alert is instantly shared across its network of over 443,000 ...
Franklin Electric Co., Inc. announced a quarterly cash dividend of $0.28 per share, payable on November 19, 2026, to shareholders of record as of November 5, 2026. This dividend reflects the company's ongoing commitment to returning value to its shar...
Eikon Therapeutics presented updated data on EIK1001, a TLR7/8 dual-agonist, combined with pembrolizumab and chemotherapy for stage 4 non-small cell lung cancer (NSCLC) at the 2026 ESMO Congress. The treatment showed a 72% objective response rate and...
